今天是2024年5月18日 星期六,欢迎光临本站 上海研生实业有限公司 网址: transbioeng.com

标记一抗

FITC标记的载脂蛋白A1抗体

文字:[大][中][小] 2017-5-3    浏览次数:927    

                                   FITC标记的载脂蛋白A1抗体                                                                                                                                                
英文名称Anti-APOA1/FITC
中文名称:FITC标记的载脂蛋白A1抗体
别    名Apo-AI; ApoA I; ApoA-I; APOA1_HUMAN; Apolipoprotein A-I(1-242); Apolipoprotein A1; Apolipoprotein A 1; Apolipoprotein AI; Apolipoprotein A I; Brp14; Ltw1; Lvtw1; Sep1; Sep2.  

详细介绍:


规格:100ul 
说 明 书100ul  
研究领域肿瘤  心血管  细胞生物  免疫学  神经生物学  信号转导  脂蛋白  新陈代谢  
抗体来源Rabbit
克隆类型Polyclonal
交叉反应 Human, Mouse, 
产品应用IF=1:50-200  
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量27kDa
性    状Lyophilized or Liquid
浓    度1mg/ml
免 疫 原KLH conjugated synthetic peptide derived from human APOA1
亚    型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

相关资料:


产品介绍background:
Apolipoprotein A I promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids; an 18 amino acid signal peptide is removed co-translationally and a 6 amino acid propeptide is cleaved post-translationally. Apolipoprotein A I is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease. The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.

返回上一步
打印此页
[向上]

网站首页

公司介绍

产品中心

技术文献

售后服务

在线留言

联系我们

在线客服

售前咨询

售后服务

咨询电话:
021-59989018

请扫描二维码
打开手机站